Immune checkpoint inhibitors plus VEGF tyrosine kinase inhibitors as second-line or later therapy for patients with extensive stage small cell lung cancer

被引：0

作者：

Yan, N. ^{[1
]}

Guo, S. X. ^{[1
]}

Li, M. J. ^{[1
]}

Huang, S. Y. ^{[1
]}

Guo, Q. Q. ^{[1
]}

Geng, D. ^{[1
]}

Zhang, H. X. ^{[1
]}

Li, X. ^{[2
]}

机构：

[1] Zhengzhou Sch Med, Affiliate Hosp 1, Oncol Dept, Zhengzhou, Peoples R China

[2] Zhengzhou Univ, Affiliated Hosp 1, Med Oncol, Zhengzhou, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.08.243

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1659P

引用

页码：S1168 / S1168

页数：1

共 50 条

[21] Immune checkpoint inhibitors in small cell lung cancer
Pakkala, Suchita
Owonikoko, Taofeek K.
JOURNAL OF THORACIC DISEASE, 2018, 10 : S460 - S467
[22] Efficacy and safety of immune checkpoint inhibitors (ICIs) in extensive-stage small cell lung cancer (SCLC)
Ma, Xiaoting
Wang, Shan
Zhang, Yujian
Wei, Huamin
Yu, Jing
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (02) : 593 - 606
[23] Efficacy and safety of immune checkpoint inhibitors (ICIs) in extensive-stage small cell lung cancer (SCLC)
Xiaoting Ma
Shan Wang
Yujian Zhang
Huamin Wei
Jing Yu
Journal of Cancer Research and Clinical Oncology, 2021, 147 : 593 - 606
[24] Current status and future perspectives of immune checkpoint inhibitors in extensive-stage small cell lung cancer
Liu, Xingyu
Xing, Huifang
Liu, Baoxing
AMERICAN JOURNAL OF CANCER RESEARCH, 2022, 12 (06): : 2447 - 2464
[25] Prognostic Factors of First-Line Immune Checkpoint Inhibitors in Combination with Chemotherapy in Extensive-Stage Small Cell Lung Cancer
Liao, Y. -T.
Sun, R. -L.
Huang, H. -C. H.
Shen, C. -I.
Tseng, Y. -H.
Luo, Y. -H.
Chen, Y. -M.
Chiang, C. -L.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S676 - S676
[26] First-line immune checkpoint inhibitors for extensive stage small-cell lung cancer: clinical developments and future directions
Ortega-Franco, A.
Ackermann, C.
Paz-Ares, L.
Califano, R.
ESMO OPEN, 2021, 6 (01)
[27] Efficacy and safety analysis of anlotinib in combination with immune checkpoint inhibitors for second-line and subsequent extensive-stage small-cell lung cancer (vol 71, pg 297, 2024)
Ying, Xixi
Shi, Zheng
Shao, Rongjun
You, Guangxian
Song, Zhengbo
NEOPLASMA, 2024, 71 (05)
[28] KEYNOTE-010: flash of a supernova (immune-checkpoint inhibitors) in second-line non-small cell lung cancer
Horinouchi, Hidehito
JOURNAL OF THORACIC DISEASE, 2017, 9 (11) : 4187 - 4190
[29] Immune Checkpoint Inhibitors plus Anti-VEGF/Tyrosine Kinase Inhibitors Combined with TACE (Triple Therapy) in Unresectable Hepatocellular Carcinoma
Kudo, Masatoshi
LIVER CANCER, 2024, 13 (03) : 227 - 234
[30] A preliminary study on drug switching strategy for second-line therapy after combination treatment of tyrosine kinase inhibitors and immune checkpoint inhibitors for unresectable hepatocellular carcinoma
Guan, Renguo
Yu, Chengyou
Li, Shaohua
Mei, Jie
Wei, Wei
Guo, Rongping
FRONTIERS IN PHARMACOLOGY, 2022, 13

← 1 2 3 4 5 →